文献速递心脑血管急症重症综合管理与镇静镇痛

急性缺血性卒中早期动脉血压调控(MAPAS):一项随机对照试验结果

Early Manipulation of Arterial Blood Pressure in Acute Ischemic Stroke (MAPAS): Results of a Randomized Controlled Trial.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论非溶栓急性缺血性卒中患者24小时内将收缩压维持在161–180 mmHg者90天良好预后概率较高,而181–200 mmHg组症状性颅内出血更多。

MAPAS试验将218例急性缺血性卒中患者随机分为三组,在发病12小时内分别将24小时收缩压维持在140–160 mmHg、161–180 mmHg或181–200 mmHg。三组90天良好预后(改良Rankin评分0–2分)无显著差异(51% vs 52% vs 39%,P=0.27),但症状性颅内出血在高收缩压组更常见(1% vs 2.7% vs 9.1%,P=0.048),死亡率相似。Logistic回归校正混杂因素后,第2组获得良好预后的比值比更高(OR 2.83)。未观察到与24小时内降压相关的急性神经功能恶化。

要点

  • 非溶栓急性缺血性卒中患者24小时内收缩压目标161–180 mmHg组症状性颅内出血2.7%,低于181–200 mmHg组的9.1%(P=0.048)。
  • 三组90天良好预后(改良Rankin评分0–2分)无显著差异:140–160 mmHg组51%、161–180 mmHg组52%、181–200 mmHg组39%(P=0.27)。
  • Logistic回归校正混杂因素后,161–180 mmHg组获得良好预后的比值比更高(OR 2.83)。
  • 无论分组,调高血压者良好预后概率47%、调低者42%、未调控者62%(P=0.1)。
  • 不良反应仅见于161–180 mmHg组(4%)和181–200 mmHg组(7.6%),且与去甲肾上腺素使用相关(P=0.05)。

适用人群与场景

  • 发病12小时内的非溶栓急性缺血性卒中患者,随机分组时纳入本研究。

诊断标准与关键阈值

  • 良好预后定义为90天改良Rankin评分0–2分。
  • 血压目标:第1组收缩压140–160 mmHg、第2组161–180 mmHg、第3组181–200 mmHg,维持24小时。

处置流程与药物剂量

  • 使用血管活性药物和液体达到上述收缩压目标,维持24小时。
  • 不良反应仅见于第2组(4%)和第3组(7.6%),且与使用去甲肾上腺素相关(P=0.05)。

红旗征与不能漏的情况

  • 症状性颅内出血在高收缩压范围更常见(第1组1% vs 第2组2.7% vs 第3组9.1%,P=0.048)。
  • 未观察到与24小时内收缩压降低相关的急性神经功能恶化。

研究设计与关键结果

  • 随机对照试验,218例患者随机分为三组,24小时内中位收缩压分别为153 mmHg、163 mmHg、178 mmHg(P<0.0001)。
  • 90天良好预后三组无显著差异:51% vs 52% vs 39%(P=0.27)。
  • 症状性颅内出血:1% vs 2.7% vs 9.1%(P=0.048),死亡率相似。
  • Logistic回归校正重要混杂因素后,第2组获得良好预后的比值比更高(OR 2.83)。
  • 无论分组,调高血压者良好预后概率47%、调低者42%、未调控者62%(P=0.1)。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,校正混杂因素后收缩压161–180 mmHg组获得良好预后的比值比更高(OR 2.83)。
  • 作者认为,症状性颅内出血在收缩压181–200 mmHg组更常见。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: There is uncertainty over the optimal level of systolic blood pressure (SBP) in the setting of acute ischemic stroke (AIS). The aim of this study was to determine the efficacy of the early manipulation of SBP in non-thrombolised patients. The key hypothesis under investigation was that clinical outcomes vary across ranges of SBP in AIS.

METHODS: 218 patients were randomized within 12 h of AIS to maintain the SBP during 24 h within three ranges: Group 1 140-160 mmHg, Group 2 161-180 mmHg or Group 3 181-200 mmHg. Vasoactive drugs and fluids were used to achieve these targets. Good outcome was defined as a modified Rankin score 0-2 at 90-days.

RESULTS: The median SBP in the three groups in 24 h was: 153 mmHg, 163 mmHg, and 178 mmHg, respectively, P < 0.0001. Good clinical outcome did not differ among the different groups (51% vs 52% vs 39%, P = 0.27). Symptomatic intracranial hemorrhage (SICH) was more frequent in the higher SBP range (1% vs 2.7% vs 9.1%, P = 0.048) with similar mortality rates. No patient had acute neurological deterioration related to the SBP reduction in the first 24 h. In our logistic regression analysis, the odds of having good clinical outcome was higher in Group 2 (OR 2.83) after adjusting for important confounders. Regardless of the assigned group, the probability of good outcome was 47% in patients who were manipulated to increase the BP, 42% to decrease and 62% in non-manipulated (P = 0.1). Adverse effects were limited to Group 2 (4%) and Group 3 (7.6%) and were associated with the use of norepinephrine (P = 0.05).

CONCLUSIONS: Good outcome in 90 days was not significantly different among the 3 blood pressure ranges. After logistic regression analysis, the odds of having good outcome was greater in Group 2 (SBP 161-180 mmHg). SICH occurred more frequently in Group 3 (181-200 mmHg).

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Nasi LA, Martins SCO, Gus M, et al. Early Manipulation of Arterial Blood Pressure in Acute Ischemic Stroke (MAPAS): Results of a Randomized Controlled Trial. Neurocrit Care. 2019. PMID: 30460598. doi:10.1007/s12028-018-0642-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。